Comparative effectiveness of silodosin vs. tamsulosin in treating acute urinary retention in benign prostatic hyperplasia patients.

IF 0.8 4区医学 Q3 MEDICINE, GENERAL & INTERNAL

Journal of the Pakistan Medical Association Pub Date : 2025-04-01 DOI:10.47391/JPMA.20668

Hassaan Ul Hassan, Tanzeel-Ur-Rahman Al Gazder, Nawaz Khan, Abbas Jafri, Asad Shahzad Hassan, Altaf Hashmi

{"title":"Comparative effectiveness of silodosin vs. tamsulosin in treating acute urinary retention in benign prostatic hyperplasia patients.","authors":"Hassaan Ul Hassan, Tanzeel-Ur-Rahman Al Gazder, Nawaz Khan, Abbas Jafri, Asad Shahzad Hassan, Altaf Hashmi","doi":"10.47391/JPMA.20668","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the effectiveness of silodosin and tamsulosin in patients with acute urine retention caused by benign prostatic hyperplasia.Methods: The prospective cohort study was conducted at the Sindh Institute of Urology and Transplantation, Karachi, from July to December 2022, and comprised male benign prostatic hyperplasia patients with acute urine retention. The patients were divided into group A receiving 0.4mg tamsulosin and group B receiving 8mg silodosin. The catheter was withdrawn after seven days. Trial without catheterisation success was measured by patients' postvoid residue. All patients were reassessed for post-void residue at 4 weeks after a successful trial without catheterisation. Data was analysed using SPSS 21.Results: Of the 130 male subjects with mean age 64.79±9.71 years, mean prostate volume 46.22±6.82ml and mean post-void residual 96±13ml on day 7 and 89.73±14.38ml on day 28, 65(50%) were in each of the two groups. Intergroup difference with respect to efficacy at four weeks was not significant (p=0.584).Conclusions: The efficacy of tamsulosin and silodosin in individuals with benign prostatic hyperplasia was comparable.","PeriodicalId":54369,"journal":{"name":"Journal of the Pakistan Medical Association","volume":"75 4","pages":"592-595"},"PeriodicalIF":0.8000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Pakistan Medical Association","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.47391/JPMA.20668","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate the effectiveness of silodosin and tamsulosin in patients with acute urine retention caused by benign prostatic hyperplasia.

Methods: The prospective cohort study was conducted at the Sindh Institute of Urology and Transplantation, Karachi, from July to December 2022, and comprised male benign prostatic hyperplasia patients with acute urine retention. The patients were divided into group A receiving 0.4mg tamsulosin and group B receiving 8mg silodosin. The catheter was withdrawn after seven days. Trial without catheterisation success was measured by patients' postvoid residue. All patients were reassessed for post-void residue at 4 weeks after a successful trial without catheterisation. Data was analysed using SPSS 21.

Results: Of the 130 male subjects with mean age 64.79±9.71 years, mean prostate volume 46.22±6.82ml and mean post-void residual 96±13ml on day 7 and 89.73±14.38ml on day 28, 65(50%) were in each of the two groups. Intergroup difference with respect to efficacy at four weeks was not significant (p=0.584).

Conclusions: The efficacy of tamsulosin and silodosin in individuals with benign prostatic hyperplasia was comparable.

查看原文本刊更多论文

西洛多辛与坦索罗辛治疗前列腺增生患者急性尿潴留的疗效比较。

目的：评价西洛多辛与坦索罗辛治疗前列腺增生所致急性尿潴留的疗效。方法：前瞻性队列研究于2022年7月至12月在卡拉奇Sindh泌尿外科和移植研究所进行，研究对象为急性尿潴留的男性良性前列腺增生患者。将患者分为两组，A组给予坦索罗辛0.4mg， B组给予西洛多辛8mg。7天后取出导管。未置管的试验成功与否通过患者的空后残留来衡量。所有患者在试验成功后4周重新评估空腔残留。数据采用SPSS 21进行分析。结果：130例男性患者，平均年龄64.79±9.71岁，第7天平均前列腺体积46.22±6.82ml，第28天平均前列腺后残留96±13ml， 89.73±14.38ml，两组各65例（50%）。4周疗效组间差异无统计学意义（p=0.584）。结论：坦索罗辛与西洛多辛治疗前列腺增生的疗效相当。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of the Pakistan Medical Association Medicine-General Medicine

CiteScore

1.10

自引率

11.10%

发文量

983

审稿时长

3-6 weeks

期刊介绍： Primarily being a medical journal, JPMA publishes scholarly research focusing on the various fields in the areas of health and medical education. It publishes original research describing recent advances in health particularly clinical studies, clinical trials, assessments of pathogens of diagnostic importance, medical genetics and epidemiological studies. Review articles highlighting importance of various issues in the domain of public health, drug research and medical education are also accepted. As a leading journal of South Asia, JPMA remains cognizant of the recent advances in the rapidly growing fields of biomedical sciences, it invites and encourages scholars to write short reviews and invited editorials on the emerging issues. We particularly aim to promote health standards of developing countries by encouraging manuscript submissions on issues affecting the public health and health delivery services.